Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs

Review

Published on 06 Nov 2025

Consensus on managing delayed methotrexate elimination in high-dose therapy: insights from the Middle East

in Pharmacology of Anti-Cancer Drugs

Mubarak Al Manasour
Ahmad Absi
Ahmad Alhuraiji
Muhammad Faisal Khanani
Kayane Mheidly
Mohamed Elsaid
Walid Ballourah
Murtadha Al-Khabori
Naser Al Zain
Nisreen Khalifa

Frontiers in Oncology

doi 10.3389/fonc.2025.1660937

383 views

Brief Research Report

Published on 05 Nov 2025

Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer

in Pharmacology of Anti-Cancer Drugs

Lucas C. M. Arruda
Julia Karbach
Dragan Kiselicki
Kathrin Brand
Claudia Wahle
Evgueni Sinelnikov
Dirk Gustavus
Hans Hoffmeister
Akin Atmaca
Elke Jäger

Frontiers in Oncology

doi 10.3389/fonc.2025.1693912

733 views

Original Research

Published on 05 Nov 2025

Artificial intelligence-based evaluation of prognostic benefits from immunotherapy plus targeted therapy with or without radiotherapy or TACE in advanced hepatocellular carcinoma

in Pharmacology of Anti-Cancer Drugs

Yuehong Deng
Shiqin Song
Huarong Zhao
Yuqian Yang
Simin Lu
Xueting Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1694565

439 views

Correction

Accepted on 04 Nov 2025

Lathyrol inhibits the proliferation of Renca cells by altering expression of TGF-β/Smad pathway components and subsequently affecting the cell cycle

in Pharmacology of Anti-Cancer Drugs

Shengyou Song
Yalin Song

Frontiers in Oncology

Original Research

Published on 03 Nov 2025

Mechanism of active component β-sitosterol from Myristica fragrans inducing apoptosis in bladder cancer cells via regulating the BCL-2/BAX/caspase-3 pathway

in Pharmacology of Anti-Cancer Drugs

Yongkang Zhu
Zhao Tang
Zhaoyue Lu
Dongyang Gao
Hao Pan
Haozhe Jiang
Zhen Zhang
Huiqing Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1698721

358 views

Original Research

Published on 29 Oct 2025

Experimental study on the treatment of norepinephrine transporter-overexpressing pheochromocytomas and paragangliomas: a synthetic lethality strategy combining 131I-MIBG with PARP inhibitors

in Pharmacology of Anti-Cancer Drugs

Jieping Song
Lulu Zhang
Fan Qiu
Xiumin Shi
Rui Tian
Chuan Zhang
Xiaoyuan Li
Feng Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1681054

234 views

Review

Accepted on 27 Oct 2025

Overcoming resistance in advanced urothelial carcinoma: Mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition

in Pharmacology of Anti-Cancer Drugs

Brandon Wummer
Michael Schwartz
Jordan Alana Ciuro
Shahid Sattar Ahmed
Shreyas Joshi
Vikram M Narayan
Bradley C Carthon
Mehmet Asim Bilen
Jacqueline Theresa Brown

Frontiers in Oncology

174 views

Review

Accepted on 22 Oct 2025

PARP Inhibitors as Radiosensitizers: A Comprehensive Review of Preclinical Evidence and Clinical Applications

in Pharmacology of Anti-Cancer Drugs

Shude Yang
Shuo Gao
Kaiyang Sun
Zhiqiang Dong
Xiaodong Luo

Frontiers in Oncology

330 views

Review

Accepted on 22 Oct 2025

Artificial Intelligence in Oncology Drug Development and Management: A Precision Medicine Perspective

in Pharmacology of Anti-Cancer Drugs

QingWei Yang
Caixia Fang
Pengfa Zhou
Xuerong Zhang
Yongsheng He

Frontiers in Oncology

530 views

Review

Published on 21 Oct 2025

Overcoming cancer drug resistance: insights into Apoptotic pathway modulation by plant-based nanoparticle and natural products

in Pharmacology of Anti-Cancer Drugs

Amit Kumar Singh
Prem Prakash Kushwaha
Ajaya Kumar Singh
Abhay K. Pandey

Frontiers in Oncology

doi 10.3389/fonc.2025.1677380

984 views

Systematic Review

Published on 15 Oct 2025

Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Yanlin Wang
Wen Sun
Bing Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1667282

1,069 views

Review

Published on 13 Oct 2025

The role of cytostatic in oxidative stress reactions

in Pharmacology of Anti-Cancer Drugs

Renata Polaniak
Aleksander Kwiatkowski
Michał Górski
Elżbieta Grochowska-Niedworok
Małgorzata Latocha

Frontiers in Oncology

doi 10.3389/fonc.2025.1667522

883 views

Case Report

Published on 13 Oct 2025

A case report of malignant hypertension and multiorgan dysfunction during immunotherapy for gallbladder cancer

in Pharmacology of Anti-Cancer Drugs

Caroline Anthon
Hugo Pierret
Frederic Houssiau
Astrid De Cuyper
Cédric Van Marcke
Marc Van Den Eynde
Filomena Mazzeo
Frank Cornelis
Rachel Galot
Francois P. Duhoux

Frontiers in Oncology

doi 10.3389/fonc.2025.1658621

764 views

Editorial

Published on 10 Oct 2025

Editorial: Drug development for pancreatic cancer: novel targets, drug candidates and mechanisms

in Pharmacology of Anti-Cancer Drugs

Xiao Sun
HongDe Xu

Frontiers in Oncology

doi 10.3389/fonc.2025.1705678

831 views

Original Research

Published on 08 Oct 2025

Lathyrol inhibits the proliferation of Renca cells by altering expression of TGF-β/Smad pathway components and subsequently affecting the cell cycle

in Pharmacology of Anti-Cancer Drugs

Shengyou Song
Yalin Song

Frontiers in Oncology

doi 10.3389/fonc.2025.1629962

888 views

Case Report

Published on 06 Oct 2025

Case Report: Bevacizumab-induced renal-limited TMA and FSGS-like lesions in a kidney transplant recipient

in Pharmacology of Anti-Cancer Drugs

Xingxing Jian
Ge Liu
Shuangyan Yu
Jie Sheng

Frontiers in Oncology

doi 10.3389/fonc.2025.1638274

979 views